Legislative Documents

Also, variously referred to as: House bills; House documents; House legislative documents; legislative documents; General Court documents

MOESM2 of Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Additional file 2: Figure S1. Patient disposition. A total of 54 patients were enrolled in this study, all of whom received sucroferric oxyhydroxide and were included in the safety analysis set (the population consisting of study subjects who received sucroferric oxyhydroxide at least once). Among these patients, 40 completed the observations in Week 8 and were included in the efficacy analysis set (the population consisting of patients who were continuing sucroferric oxyhydroxide treatment in Week 8 and have at least 1 analyzable data point for the efficacy endpoints in and after Week 8). Six patients were newly administered calcium carbonate after the start of the study. Ten patients were administered sucroferric oxyhydroxide in addition to calcium carbonate monotherapy (Adding group). Therefore, 24 patients were switched from existing hyperphosphatemia agents to sucroferric oxyhydroxide (Switching group). After the start of the study, 21 patients discontinued, and 33 patients completed the observations in Week 16

MOESM3 of Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Additional file 3: Table S1. Patient demographics and clinical characteristics (Switching group, n = 24)

MOESM11 of Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Additional file 11: Table S7. Adverse reactions of the Switching group and the Adding group

MOESM1 of Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Additional file 1: Additional methods. Additional study design and statistical analysis

MOESM8 of Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Additional file 8: Figure S3. Time point at which target serum phosphorus level was achieved (Switching group, n = 24). The breakdown of the first time of achieving the target serum phosphorus level (≥ 3.5 and ≤ 6 mg/dL) in the 24 patients (Switching group)

MOESM4 of Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Additional file 4:Figure S2. Time point at which target serum phosphorus level was achieved (All, n = 40). The breakdown of the first time of achieving the target serum phosphorus level (≥ 3.5 and ≤ 6 mg/dL) in the 40 patients of the efficacy analysis set

MOESM5 of Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Additional file 5: Table S2. Efficacy parameters of the Switching group and the Adding group (CKD-MBD parameters)

MOESM6 of Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Additional file 6: Table S3. Efficacy parameters of the Switching group and the Adding group (renal anemia parameter)

MOESM7 of Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Additional file 7: Table S4. Efficacy parameters of the Switching group and the Adding group (drug administration status)